



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/33, A61K 39/08, 38/46		A2	(11) International Publication Number: WO 99/09057
			(43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/EP98/05113		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 12 August 1998 (12.08.98)			
(30) Priority Data: 60/055,615 14 August 1997 (14.08.97) US 60/065,236 13 November 1997 (13.11.97) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): INSTITUT PASTEUR [FR/FR]; 25-28, rue du Docteur Roux, F-75724 Paris Cedex 15 (FR).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): COEN, Laurent [FR/FR]; 9, rue Beaumarchais, F-93400 Montreuil (FR). OSTA PINZOLAS, Rosario [ES/ES]; Calle Mariano Barbasan, 16 2ºC, E-50006 Zaragoza (ES). BRULET, Philippe [FR/FR]; 61, rue de Lourmel, F-75015 Paris (FR).			
(74) Agents: GUTMANN, Ernest et al.; Ernest Gutmann-Yves Plasseraud S.A., 3, rue Chauveau-Lagarde, F-75008 Paris (FR).			
(54) Title: HYBRID TETANUS TOXOID PROTEINS THAT MIGRATE RETROGRADELY AND TRANSYNAPTICALLY INTO THE CNS			
<p>(57) Abstract</p> <p>The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins <i>in vivo</i>, i.e. retrograde transsynaptic transport of the TTC fragment and -gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.</p>			

HYBRID TETANUS TOXOID PROTEINS THAT MIGRATE RETROGRADELY AND TRANSYNAPTICALLY INTO THE CNS

BACKGROUND OF THE INVENTION

This invention relates to the use of part of tetanus toxin for delivering a composition to the central nervous system of a human or animal. This invention also relates to a hybrid fragment of tetanus toxin, a polynucleotide that hybridizes with natural tetanus toxin, and a composition containing the tetanus toxin fragment as an active molecule. Further, this invention relates to a vector comprising a promoter and a nucleic acid sequence encoding the tetanus toxin fragment.

Tetanus toxin is produced by *Clostridium tetani* as an inactive, single, polypeptide chain of 150 kD composed of three 50kD domains connected by protease-sensitive loops. The toxin is activated upon selective proteolytic cleavage, which generates two disulfide-linked chains: L (light, 50kD) and H (heavy, 100 kD) [Montecucco C. and Schiavo G. Q. Rev. Biophys., (1995), 28 : 423-472].

Evidence for the retrograde axonal transport of tetanus toxin to central nervous system (CNS) has been described by Erdmann et al. [Naunyn Schmiedebergs Arch Pharmacol., (1975), 290:357-373], Price et al. [Science, (1975), 188:945-94], and Stoeckel et al. [Brain Res.,

(1975), 99:1-16]. In each of these studies, radiolabeled toxin was found inside membrane bound vesicles. Another property was the transsynaptic movement of tetanus toxin that was demonstrated first by autoradiographic localization of 125 I -labeled tetanus toxin in spinal cord interneurons after injection into a muscle [Schwab and Thoenen, Brain res., (1976), 105:218-227].

The structure of this tetanus toxin has been elucidated by Helting et al. [J.Biol. Chem., (1977), 252:187-193]. Papain cleaves the tetanus toxin in two fragments:

- the C terminal part of the heavy chain, 451 amino acids, also called fragment C; and
- the other part contained the complementary portion called fragment B linked to the light chain (fragment A) via a disulfide bond.

European Patent No. EP 0 030 496 B1 showed the retrograde transport of a fragment B-II_b to the CNS and was detected after injection in the median muscle of the eye in primary and second order neurons. This fragment may consist of "isofragments" obtained by clostridial proteolysis. Later, this fragment B-II_b was demonstrated to be identical to fragment C obtained by papain digestion by Eisel et al. [EMBO J., 1986, 5:2495-2502].

This EP patent also demonstrated the retrograde transport of a conjugate consisting of a I_{bc} tetanus toxin fragment coupled by a disulfide bond to B-II_b from axonal endings within the muscle to the motoneuronal perikarya and pericellular spaces. (The I

bc fragment corresponds to the other part obtained by papain digestion as described above by Helting et al.). There is no evidence that this conjugate was found in second order neurons. The authors indicated that a conjugate consisting of the fragment B-II_b coupled by a disulfide bond to a therapeutic agent was capable of specific fixation to gangliosides and synaptic membranes. No result showed any retrograde axonal transport or a transsynaptic transport for such conjugate.

Another European Patent, No. EP 0 057 140 B1, showed equally the retrograde transport of a fragment II_c to the CNS. As in the European Patent No. EP 0 030 496 B1, the authors indicated that a conjugate consisting of the fragment II_c and a therapeutic agent was capable of specific fixation, but no result illustrated such allegation. This fragment II_c corresponds to the now called fragment C obtained by papain digestion.

Francis et al. [J. Biol. Chem., (1995), 270(25):15434-15442] just led an *in vitro* study showing the internalization by neurons of hybrid between SOD-1 (Cu Zn superoxide dismutase) and a recombinant C tetanus toxin fragment by genetic recombination. This recombinant C tetanus toxin fragment was obtained from Halpern group. (See ref. 11).

Moreover, Kuypers H. G. J. M and Ugolini G. [TINS, (1990), 13(2):71-75] indicated in their publication concerning viruses as transneuronal tracers that, despite the fact that tetanus toxin fragment binds to specific receptors on neuronal membranes, transneuronal

labeling is relatively weak and can be detected only in some of the synaptically connected neurons.

Notwithstanding these advances in the art, there still exists a need for methods for delivering compositions into the human or animal central nervous system. There also exists a need in the art for biological agents that can achieve this result.

SUMMARY OF THE INVENTION

This invention aids in fulfilling these needs in the art. More particularly, this invention provides a method for *in vivo* delivery of desired composition into the central nervous system (CNS) of the mammal, wherein the composition comprises a non-toxic proteolytic fragment of tetanus toxin (TT) in association with at least a molecule having a biological function. The composition is capable of *in vivo* retrograde transport and transsynaptic transport into the CNS and of being delivered to different areas of the CNS.

This invention also provides a hybrid fragment of tetanus toxin comprising fragment C and fragment B or a fraction thereof of at least 11 amino acid residues or a hybrid fragment of tetanus toxin comprising fragment C and fragment B or a fraction thereof of at least 11 amino acid residues and a fraction of fragment A devoid of its toxic activity corresponding to the proteolytic domain having a Zinc-binding motif located in the central part of the chain between the amino acids 225 and 245, capable of transferring *in vivo* a protein, a peptide, or a polynucleotide through a neuromuscular junction and at least one synapse.

Further, this invention provides a composition comprising an active molecule in association with the hybrid fragment of tetanus toxin (TT) or a variant thereof. The composition is useful for the treatment of a patient or an animal affected with CNS disease, which comprises delivering a composition of the invention to the patient or animal. In addition, the composition of this invention may be useful to elicit a immune response in the patient or animal affected with CNS, which comprises delivering a composition of the invention to the patient or animal.

Moreover, this invention provides polynucleotide variant fragments capable of hybridizing under stringent conditions with the natural tetanus toxin sequence. The stringent conditions are for example as follows: at 42 C for 4 to 6 hours in the presence of 6 x SSC buffer, 1 x Denhardt's Solution, 1% SDS, and 250 μ g/ml of tRNA. (1 x SSC corresponds to 0.15 M NaCl and 0.05 M sodium citrate; 1 x Denhardt's solution corresponds to 0.02% Ficoll, 0.02% polyvinyl pyrrolidone and 0.02% bovine serum albumin). The two wash steps are performed at room temperature in the presence of 0.1 x SCC and 0.1% SDS.

A polynucleotide variant fragment means a polynucleotide encoding for a tetanus toxin sequence derived from the native tetanus toxin sequence and having the same properties of transport.

In addition, the invention provides a vector comprising a promoter capable of expression in muscle cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin of

the invention or an amino acid variant fragment of the invention associated with a polynucleotide coding for a protein or a polypeptide of interest. In a preferred embodiment of the invention the promoter can be the CMV promoter and preferably the CMV promoter contained in pcDNA 3.1 (In Vitrogen, ref. V790-20), or the promoter actin as described in Bronson S.V. et al. (PNAS, 1996), 93:9067-9072).

In addition, the invention provides a vector comprising a promoter capable of expression in neuronal cells or in precursors (such NT2(hNT) precursor cells from Stratagen reference # 204101) and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin of the invention or an amino acid variant fragment of the invention associated with a polynucleotide coding for a protein or a polypeptide of interest. In a preferred embodiment of the invention the promoter can be actin (see the above reference). These vectors are useful for the treatment of a patient or an animal infected with CNS disease comprising delivering the vector of the invention to the patient or animal. In addition, these vectors are useful for eliciting immune responses in the patient or animal.

One advantage of the present invention comprising the fragment of tetanus toxin (fragment A, B, and C) is to obtain a better transport of the fragment inside the organism compared with fragment C. Another advantage of the composition of the invention is to obtain a well defined amino acid sequence and not a multimeric

composition. Thus, one can easily manipulate this composition in gene therapy.

BRIEF DESCRIPTION OF THE DRAWINGS

This invention will be more fully described with reference to the drawings in which:

FIGURE 1 shows the DNA sequence and amino acid sequence of the TTC fragment cloned in pBS:TTC.

FIGURE 2 shows the details of construct pBS:TTC.

TTC cDNA isolation:

The TTC cDNA was isolated from a Clostridium Tetani strain using Polymerase Chain Reaction. A three times PCR was used to generate three overlapping fragments respectively of 465 bp (PCR1; primer 1: 5'CCC CCC GGG CCA CCA TGG TTT TTT CAA CAC CAA TTC CAT TTT CTT ATT C-3' & primer 2: 5'-CTA AAC CAG TAA TTT CTG-3'), of 648 bp (PCR2; primer 3: 5'-AAT TAT GGA CTT TAA AAG ATT CCG C-3' & primer 4: 5'GGC ATT ATA ACC TAC TCT TAG AAT-3') and of 338 bp (PCR3; primer 5: 5'-AAT GCC TTT AAT AAT CTT GAT AGA AAT-3' & primer 6: 5'-CCC CCC GGG CAT ATG TCA TGA ACA TAT CAA TCT GTT TAA TC-3'), and each fragment was sequentially cloned into pBluescript KS+ to produce plasmid pBS-TTC. The upstream primer 1 contained the Ribosome Binding Site (RBS) and translation initiation signals.

FIGURE 3 depicts pGEX:lacZ-TTC construct.

FIGURE 4 shows construct pGEX:TTC-lacZ.

FIGURE 5 depicts the details of the construct pCMV:lacZ-TTC.

DETAILED DESCRIPTION

Tetanus toxin is a potent neurotoxin of 1315 amino acids that is produced by *Clostridium tetani* (1, 2). It prevents the inhibitory neurotransmitter release from spinal cord interneurons by a specific mechanism of cell intoxication (for review see ref 3). This pathological mechanism has been demonstrated to involve retrograde axonal and transsynaptic transport of the tetanus toxin. The toxin is taken up by nerve endings at the neuromuscular junction, but does not act at this site; rather, the toxin is transported into a vesicular compartment and travels along motor axons for a considerable distance until it reaches its targets. The transsynaptic movement of tetanus toxin was first demonstrated by autoradiographic localization in spinal cord interneurons after injection into a muscle (4). However, previous studies of transsynaptic passage of

tetanus toxin from motoneurons were limited by the rapid development of clinical tetanus and death of the experimental animal (4, 5, 6).

A fragment of tetanus toxin obtained by protease digestion, the C fragment, has been shown to be transported by neurons in a similar manner to that of the native toxin without causing clinical symptoms (7, 8, 9, 10). A recombinant C fragment was reported to possess the same properties as the fragment obtained by protease digestion (11). The fact that an atoxic fragment of the toxin molecule was able to migrate retrogradely within the axons and to accumulate into the CNS led to speculation that such a fragment could be used as a neurotrophic carrier (12). A C fragment chemically conjugated to various large proteins was taken up by neurons in tissue culture (13) and by motor neurons in animal models (ref. 12, 14, and 15). According to the invention the fragment of tetanus toxin consists of a non-toxic proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues or a non-toxic proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acids residues and a fraction of a fragment A devoid of its toxic activity corresponding to the proteolytic domain having a zinc-binding motif located in the central part of the chain between the amino acids 225 and 245 (cf. Montecucco C. and Schiavo G. Q. Rev. Biophys., (1995), 28:423-472). Thus the fraction of the fragment A comprises, for example, the amino acid

sequence 1 to 225 or the amino acid sequence 245 to 457, or the amino acid sequence 1 to 225 associated with amino acid sequence 245 to 457.

The molecule having a biological function is selected from the group consisting of protein of interest, for example, for the compensation or the modulation of the functions under the control of the CNS or the spinal cord or the modulation of the functions in the CNS or the spinal cord, or protein of interest to be delivered by gene therapy expression system to the CNS or the spinal cord. The proteins of interest are, for example, the protein SMN implicated in spinal muscular atrophy (Lefebvre et al., *Cell*, (1995), 80:155-165 and Roy et al., *Cell*, (1995), 80:167-178); neurotrophic factors, such as BDNF (Brain-derived neurotrophic factor); NT-3 (Neurotrophin-3); NT-4/5; GDNF (Glial cell-line-derived neurotrophic factor); IGF (Insulin-like growth factor) (Oppenheim, *Neuron*, (1996), 17:195-197 ; Thoenen et al., *Exp. Neurol.*, (1993), 124:47-55 and Henderson et al., *Adv. Neurol.*, (1995), 68:235-240); or PNI (protease nexin I) promoting neurite outgrowth (this factor can be used for the treatment of Alzheimer disease (Houenou et al., *PNAS*, (1995), 92:895-899)); or SPI3 a serine protease inhibitor protein (Safaei, *Dev. Brain Res.*, (1997), 100: 5-12); or ICE (Interleukin-1 converting Enzyme) a factor implicated in apoptosis, to avoid apoptosis (Negata, *Cell*, (1997), 88:355-365); or Bcl-2, a key intracellular regulator of programmed cell death (Jacobson, M.D. (1997), *Current Biology*, 7:R277-R281); or green fluorescent protein (Lang et al., *Neuron*,

(1997), 18:857-863) as a marker; enzyme (ex : β -Gal);
2 endonuclease like I-SceI (Choulika A., et al. (1995),
3 Molecular and Cellular biology, 15 (4):1968-1973 or CRE
4 (Gu H., et al. (1994), Science, 265:103-106); specific
5 antibodies; drugs specifically directed against
6 neurodegenerative diseases such as latero spinal
7 amyotrophy. Several molecules can be associated with a
8 TT fragment.

9 In association means an association obtained by
10 genetic recombination. This association can be
11 realized upstream as well as downstream to the TT
12 fragment. The preferred mode of realization of the
13 invention is upstream and is described in detail; a
14 downstream realization is also contemplated. (Despite
15 Halpern et al., J. Biol. Chem., (1993), 268(15):11188-
16 11192, who indicated that the carboxyl-terminal amino
17 acids contain the domain required for binding to
18 purified gangliosides and neuronal cells.)

19 The desired CNS area means, for example, the
20 tongue which is chosen to direct the transport to
21 hypoglossal motoneuron; the arm muscle which is chosen
22 to direct the transport to the spinal cord motoneurons.

23 For this realization of transplantation of a
24 neuron to the CNS or the spinal cord see Gage, F.H. et
25 al. (1987), Neuroscience, 23:725-807, "Grafting
26 genetically modified cells to the brain: possibilities
27 for the future."

28 The techniques for introducing the polynucleotides
29 to cells are described in U.S. Patent Nos. 5,580,859
30 and 5,589,466, which is relied upon and incorporated by
reference herein. For example, the nucleotides may be

introduced by transfection *in vitro* before reimplantation in area of the CNS or the spinal cord.

A chemical linkage is considered for a particular embodiment of the invention and comprises the association between the TT fragment and a polynucleotide encoding the molecule of interest with its regulatory elements, such as promoter and enhancer capable of expressing said polynucleotide. Then the TT fragment allows the retrograde axonal transport and/or the transsynaptic transport, and the product of the polynucleotide is expressed directly in the neurons. This chemical linkage can be covalent or not, but preferably covalent performed by thiolation reaction or by any other binding reaction as described in "Bioconjugate Techniques" from Gret T. Hermanson (Academic press, 1996).

The axonal retrograde transport begins at the muscle level, where the composition of interest is taken up at the neuromuscular junction, and migrates to the neuronal body of the motoneurons (which are also called the first order neurons) in the CNS or spinal cord. First order neurons mean neurons that have internalized the composition of interest, and thus in this case, correspond to motoneurons.

The transsynaptic retrograde transport corresponds to interneuron communications via the synapses from the motoneurons, and comprises second order neurons and higher order neurons (fourth order corresponding to neurons in the cerebral cortex).

The different stages of the neuronal transport are through the neuromuscular junction, the motoneuron,

also called first order neuron, the synapse at any stage between the neurons of different order, neuron of order second to fourth order, which corresponds to the cerebral cortex.

In one embodiment of this invention, it is shown that a -gal-TTC (TT-fragment C) hybrid protein retains the biological activities of both proteins *in vivo*. Therefore, the hybrid protein can undergo retrograde and transneuronal transport through a chain of interconnected neurons, as traced by its enzymatic activity. These results are consistent with those of others who used chemically conjugated TTC, or TTC fused to other proteins (12, 13, 14, 15). In these *in vitro* analyses, the activity of the conjugated or hybrid proteins was likewise retained or only weakly diminished. Depending on the nature of the TTC fusion partner, different types of potential applications can be envisioned. For example, this application can be used to deliver a biologically active protein into the CNS for therapeutic purposes. Such hybrid genes can also be used to analyze and map synaptically connected neurons if reporters, such as *lacZ* or the green fluorescent protein (GFP; 29) gene, were fused to TTC.

The retrograde transport of the hybrid protein may be demonstrated as follows. When injected into a muscle, -gal activity rapidly localized to the somata of motoneurons that innervate the muscle. The arborization of the whole nerve, axon, somata and dendrites can easily be visualized. However, in comparison to the neurotropic viruses, the extent of retrograde transneuronal transport of the hybrid

protein from the hypoglossal neurons indicates that only a subset of interconnected neurons is detected, although most areas containing second-order interneurons have been identified by the β -gal-TTC marker. Transneuronal uptake is mostly restricted to second order neurons. In such experiments, when a limited amount of a neuronal tracer is injected into a muscle or cell, only a fraction will be transported through a synapse, thereby imposing an experimental constraint on its detection. Presently, the most efficient method, in terms of the extent of transport, relies on neurotropic viruses. Examples include: alpha-herpes viruses, such as herpes simplex type 1 (HSV-1), pseudorabies virus (PrV), and rhabdoviruses (24, 25). Viral methods are very sensitive because each time a virus infects a new cell, it replicates, thereby amplifying the signal and permitting visualization of higher order neurons in a chain. Ultimately, however, one wants to map a neuronal network in an *in vivo* situation such as a transgenic animal. Here, the disadvantage of viral labeling is its potential toxicity. Most viruses are not innocuous for the neural cell, and their replication induces a cellular response and sometimes cell degeneration (24). Furthermore, depending on experimental conditions, budding of the virus can occur leading to its spread into adjoining cells and tissues.

Differences in mechanisms of transneuronal migration could also account for the restricted number of neurons labeled by β -gal-TTC. Matteoli et al have provided strong evidence that the intact tetanus toxin

crosses the synapses by parasitizing the physiological process of synaptic vesicle recycling at the nerve terminal (22). The toxin probably binds to the inner surface of a synaptic vesicle during the time the lumen is exposed to the external medium. Vesicle endocytosis would then presumably provide the mechanism for internalization of the toxin. Because the TTC fragment is known to mimic the migration of the toxin *in vivo*, it could therefore direct the fusion protein along a similar transsynaptic pathway. If this hypothesis is confirmed, it would strongly suggest that synaptic activity is required for the transneuronal transport of -gal-TTC. Therefore, only active neuronal circuits would be detected by the hybrid protein. The possible dependence of -gal-TTC on synaptic vesicle exocytosis and endocytosis could be further investigated, since techniques are now available to record synaptic activity in neural networks *in vitro* (30). In contrast, the transneuronal pathway of neurotropic viruses has not yet been elucidated and could be fundamentally different, involving virus budding in the vicinity of a synapse. Finally, the transneuronal transport of the hybrid protein might depend on a synaptic specificity, although the tetanus toxin is not known to display any (7, 23). It is therefore likely that a virus would cross different or inactive synapses. In summary, the restricted spectrum of interneuronal transport, in addition to its non-toxicity, make the -gal-TTC hybrid protein a novel and powerful tool for analysis of neural pathways.

1 One advantage of the fusion gene of the invention
2 for neuronal mapping is that it derives from a single
3 genetic entity that is amenable to genetic manipulation
4 and engineering. Several years ago, a technique based
5 on homologous recombination in embryonic stem cells was
6 developed to specifically replace genes in the mouse
7 (31, 32). This method generates a null mutation in the
8 substituted gene, although in a slightly modified
9 strategy, a dicistronic messenger RNA can also be
10 produced (33, 34). When a reporter gene, such as
11 *E.coli lacZ*, is used as the substituting gene, this
12 technique provides a means of marking the mutated cells
13 so that they can be followed during embryogenesis.
14 Thus, this technique greatly simplifies the analysis of
15 both the heterozygote expression of the targeted gene
16 as well as the phenotype of null (homozygous) mutant
17 animals.

18 Another advantage of this invention is that the
19 composition comprising the fusion gene may encode an
20 antigen or antigens. Thus, the composition may be used
21 to elicit an immune response in its host and
22 subsequently confer protection of the host against the
23 antigen or antigens expressed. These immunization
24 methods are described in Robinson et al., U.S. Patent
25 No. 5,43,578, which is herein incorporated by
reference. In particular, the method of immunizing a
patient or animal host comprises introducing a DNA
transcription unit encoding comprising the fusion gene
of this invention, which encodes a desired antigen or
antigens. The uptake of the DNA transcription unit by
the host results in the expression of the desired

antigen or antigens and the subsequent elicitation of humoral and/or cell-mediated immune responses.

Neural cells establish specific and complex networks of interconnected cells. If a gene were mutated in a given neural cell, we would expect this mutation to have an impact on the functions of other, interconnected neural cells. With these considerations in mind, a genetic marker that can diffuse through active synapses would be very useful in analyzing the effect of the mutation. In heterozygous mutant animals, the cells in which the targeted gene is normally transcribed could be identified, as could the synaptically connected cells of a neural network. In a homozygous animal, the impact of the mutation on the establishment or activity of the neural network could be determined. The feasibility of such an *in vivo* approach depends critically on the efficiency of synaptic transfer of the fusion protein, as well as its stability and cellular localization.

Another extension of the invention is to gene therapy applied to the CNS. This invention provides for uptake of a non-toxic, enzyme-vector conjugate by axon terminals and conveyance retrogradely to brainstem motoneurons. A selective retrograde transsynaptic mechanism subsequently transports the hybrid protein into second-order connected neurons. Such a pathway, which by-passes the blood-brain barrier, can deliver macromolecules to the CNS. In fact, pathogenic agents, such as tetanus toxin and neurotropic viruses, are similarly taken up by nerve endings, internalized, and retrogradely transported to the nerve cell somata. In

such a scenario, the *lacZ* reporter would be replaced by a gene encoding a protein that provides a necessary or interesting activity and/or function. For example, the human CuZn superoxide dismutase, SOD-1, and the human enzyme β -N-acetylhexosaminidase A, HexA, have been fused or chemically coupled to the TTC fragment (13, 16), and their uptake by neurons *in vitro* was considerably increased and their enzymatic functions partially conserved. Combined with the *in vivo* experiments described here using β -gal-TTC, a gene therapy approach based on TTC hybrid proteins appears to be a feasible method of delivering a biological function to the CNS. However, ways have to be found to target the TTC hybrid proteins, which are likely to be sequestered into vesicles, to the appropriate subcellular compartment. Such a therapeutic strategy could be particularly useful for treating neurodegenerative and motoneuron diseases, such as amyotrophy lateral sclerosis (ALS, 35), spinal muscular atrophies (SMA, 36, 37), or neurodegenerative lysosomal storage diseases (38, 39). Injection into selected muscles, even *in utero*, could help to specifically target the appropriate neurons. In addition, such an approach would avoid the secondary and potentially toxic effects associated with the use of defective viruses to deliver a gene (40, 41).

EXAMPLES

EXAMPLE 1: Plasmid constructions.

(A) TTC cloning:

Full length TTC DNA was generated from the genomic DNA from the *Clostridium Tetani* strain (a gift from Dr.

1 M. Popoff, Institut Pasteur) using PCR. Three
2 overlapping fragments were synthesized: PCR1 of 465 bp
3 (primer 1: 5'-CCC CCC GGG CCA CCA TGG TTT TTT CAA CAC
4 CAA TTC CAT TTT CTT ATT C-3' and primer 2: 5'-CTA AAC
5 CAG TAA TTT CTG-3'), PCR2 of 648 bp (primer 3: 5'-AAT
6 TAT GGA CTT TAA AAG ATT CCG C-3' and primer 4: 5'-GGC
7 ATT ATA ACC TAC TCT TAG AAT-3') and PCR3 of 338 bp
8 (primer 5: 5'-AAT GCC TTT AAT AAT CTT GAT AGA AAT-3'
9 and primer 6: 5'-CCC CCC GGG CAT ATG TCA TGA ACA TAT
10 CAA TCT GTT TAA TC-3'). The three fragments were
11 sequentially introduced into pBluescript KS+
12 (Stratagene) to give pBS:TTC plasmid. The upstream
13 primer 1 also contains an optimized eukaryotic Ribosome
14 Binding Site (RBS) and translational initiation
15 signals. Our TTC fragment (462 amino acids) represents
16 the amino acids 854-1315 of tetanus holotoxin, i.e. the
17 carboxy-terminal 451 amino acids of the heavy chain,
18 which constitute the fragment C plus 11 amino acids of
19 the heavy chain that immediately precede the amino
20 terminus of the fragment C. The DNA sequence and amino
21 acid sequence^(45,6) of the TTC fragment cloned in pBS:TTC is
22 shown in Figure 1. The construct pBS:TTC is shown in
23 Figure 2.

24 (B) pGEX: lacZ-TTC:

25 pGEX: lacZ was obtained by cloning a *SmaI/XhoI* lacZ
26 fragment from the pGNA vector (a gift from Dr. H. Le
27 Mouellic) into pGEX 4T-2 (Pharmacia). PCR was used to
28 convert the lacZ stop codon into an *NcoI* restriction
29 site. Two primers (upstream: 5'-CTG AAT ATC GAC GGT
30 TTC CAT ATG-3' and downstream: 5'-GGC AGT CTC GAG TCT
31 AGA CCA TGG CTT TTT GAC ACC AGA C-3') were used to

1 amplify the sequence between *NdeI* and *XhoI*, generating
2 pGEX: lacZ (*NcoI*) from pGEX: lacZ. pGEX: lacZ-TTC was
3 obtained by insertion of the TTC *NcoI/XhoI* fragment
4 into pGEX: lacZ (*NcoI*), fusing TTC immediately downstream
5 of the lacZ coding region and in the same reading
6 frame. Figure 3 shows the details of the pGEX: lacZ-TTC
7 construct.

8 (C) pGEX:TTC-lacZ:

9 pBS:TTC was modified to change *NcoI* into a *BamHI*
10 restriction site (linker 5'-CAT GAC TGG GGA TCC CCA GT-
11 3') at the start of the TTC DNA, to give pBS:TTC (*BamHI*)
12 plasmid. pGEX:TTC was obtained by cloning the TTC
13 *BamHI/SmaI* fragment from pBS:TTC (*BamHI*) into pGEX 4T-2
14 (Pharmacia). PCR was used to convert the TTC stop
15 codon into an *NheI* restriction site. Two primers
16 (upstream: 5'-TAT GAT AAA AAT GCA TCT TTA GGA-3' and
17 downstream: 5'-TGG AGT CGA CGC TAG CAG GAT CAT TTG TCC
18 ATC CTT C-3') were used to amplify the sequence between
19 *NsiI* and *SmaI*, generating pGEX:TTC (*NheI*) from pGEX:TTC.
20 The lacZ cDNA from plasmid pGNA was modified in its 5'
21 extremity to change *SacII* into an *NheI* restriction site
22 (linker 5'-GCT AGC GC-3'). pGEX:TTC-lacZ was obtained
23 by insertion of the lacZ *NheI/XhoI* fragment into
24 pGEX:TTC (*NheI*), fusing lacZ immediately downstream of
25 the TTC coding region and in the same reading frame.
26 The details of the construct of pGEX:TTC-lacZ are shown
27 in Figure 4.

28 (D) pCMV: lacZ-TTC:

29 pCMV vector was obtained from pGFP-C1 (Clontech
30 laboratories) after some modifications: GFP sequence
31 was deleted by a *BglII/NheI* digestion and reigation,

1 and *SacII* in the polylinker was converted into an *AscI*
2 restriction site (linkers 5'-GAT ATC GGC GCG CCA GC-3'
3 and 5'-TGG CGC GCC GAT ATC GC-3').

4 pBluescript KS+ (Stratagene) was modified to
5 change *XhoI* into an *AscI* restriction site (linker 5'-
6 TCG ATG GCG CGC CA-3'), giving pBS(*AscI*) plasmid.
7 pBS:*lacZ*-TTC was obtained by cloning a *XmaI* *lacZ*-TTC
8 fragment from pGEX:*lacZ*-TTC into pBS(*AscI*). pCMV:*lacZ*-
9 TTC was obtained by insertion of the *lacZ*-TTC *XmnI/AscI*
10 fragment into pCMV vector at the *XhoI* and *AscI* sites
(*XhoI* and *XmnI* was eliminated with the clonage),
putting the fusion downstream of the CMV promotor.
Figure 8 shows the details of the construct pCMV:*lacZ*-
TTC. Plasmid pCMV:*lacZ*-TTC was deposited on August 12,
1997, at the Collection Nationale de Cultures de
Microorganisms (CNCM), Institut Pasteur, 25, Rue de
Docteur Roux, F-75724, Paris Cedex 15, France, under
Accession No. I-1912.

EXAMPLE 2: Purification of the hybrid protein.

The *E. coli* strain SR3315 (a gift from Dr. A. Pugsley, Institut Pasteur) transfected with pGEX:*lacZ*-TTC was used for protein production. An overnight bacterial culture was diluted 1:100 in LB medium containing 100 µg/ml ampicillin, and grown for several hours at 32 C until an OD of 0.5 was reached. Induction from the Ptac promoter was achieved by the addition of 1 mM IPTG and 1mM MgCl₂, and a further 2 hrs incubation. The induced bacteria were pelleted by centrifugation for 20 min at 3000 rpm, washed with PBS and resuspended in lysis buffer containing 0.1M Tris pH 7.8, 0.1M NaCl, 20% glycerol, 10mM EDTA, 0.1% Triton-

X100, 4mM DTT, 1 mg/ml lysosyme, and a mixture of anti-proteases (100 µg/ml Pefablok, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM benzamidine). After cell disruption in a French Press, total bacterial lysate was centrifuged for 10 min at 30000 rpm. The resulting supernatant was incubated overnight at 4 °C with the affinity matrix Glutathione Sepharose 4B (Stratagene) with slow agitation. After centrifugation for 5 min at 3000 rpm, the matrix was washed three times with the same lysis buffer but without lysosyme and glycerol, and then three times with PBS. The resin was incubated overnight at 4 °C with Thrombin (10U/ml; Sigma) in PBS in order to cleave the -gal-TTC fusion protein from the Glutathione-S-transferase (GST) sequence and thereby elute it from the affinity column. Concentration of the eluted fusion protein was achieved by centrifugation in centricon X-100 tubes (Amicon; 100,000 MW cutoff membrane).

Purified hybrid protein was analyzed by Western blotting after electrophoretic separation in 8% acrylamide SDS/PAGE under reducing conditions followed by electrophoretic transfer onto nitrocellulose membranes (0.2 mm porosity, BioRad). Immunodetection of blotted proteins was performed with a Vectastain ABC-alkaline phosphatase kit (Vector Laboratories) and DAB color development. Antibodies were used as follows: rabbit anti- -gal antisera (Capel), dilution 1:1000; rabbit anti-TTC antisera (Calbiochem), dilution 1:20000. A major band with a relative molecular mass of 180 kDa corresponding to the -Gal-TTC hybrid

protein was detected with both anti- β -Gal anti-TTC antibodies.

EXAMPLE 3: Binding and internalization of recombinant protein in differentiated 1009 cells.

The 1009 cell line was derived from a spontaneous testicular teratocarcinoma arising in a recombinant inbred mouse strain (129 x B6) (17). The 1009 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and passaged at subconfluence. *In vitro* differentiation with retinoic acid and cAMP was performed as described (18). Eight days after retinoic acid treatment, cells were used for the internalization experiments with either the hybrid protein or β -gal.

Binding and internalization of the β -Gal-TTC fusion were assessed using a modified protocol (16). Differentiated 1009 cells were incubated for 2 hrs at 37°C with 5 μ g/ml of β -Gal-TTC or β -Gal protein diluted in binding buffer (0.25% sucrose, 20mM Tris acetate 1mM CaCl₂, 1mM MgCl₂, 0.25% bovine serum albumin, in PBS). The cells were then incubated with 1 μ g/ml Pronase E (Sigma) in PBS for 10 min at 37°C, followed by washing with proteases inhibitors diluted in PBS (100 μ g/ml Pefablok, 1 mM benzamidine).

The cells were fixed with 4% formalin in PBS for 10 min at room temperature (RT) and then washed extensively with PBS. β -gal activity was detected on fixed cells by an overnight staining at 37°C in X-Gal solution (0.8 mg/ml X-Gal, 4mM potassium ferricyanide, 4mM potassium ferrocyanide, 4mM MgCl₂ in PBS). For

electron microscopy, the cells were further fixed in 2.5% glutaraldehyde for 18 hrs, and then processed as described (19).

For immunohistochemical labeling, cells were fixed with 4% paraformaldehyde in PBS for 10 min at RT then washed extensively with PBS, followed by a 1 hr incubation at RT with 2% BSA/0.02% Triton X-100 in PBS. Cells were co-incubated in primary antibodies diluted in 2% BSA/0.02% Triton X-100 in PBS for 2 hrs at RT. Antibodies used were a mouse anti-neurofilament antibody (NF 200 Kd, dilution 1:50; Sigma) or the rabbit anti-TTC antibody (dilution 1:1000). The labeling was visualized using fluorescent secondary antibodies: Cy3, goat anti-rabbit IgG (dilution 1:500; Amersham) or anti-mouse IgG with extravidin-FITC (dilution 1:200; Sigma). Cells were mounted in mowiol and visualized with epifluorescence.

EXAMPLE 4: In vivo recombinant protein injection.

14-week old B6D2F1 mice were obtained from IFFA-CREDO. The animal's tongue muscle was injected using an Hamilton syringe (20 μ l per animal) while under general anesthesia with 3% Avertin (15 μ l/g of animal). The protein concentration was 0.5 to 5 μ g/ μ l in PBS; therefore, mice received approximately 10 to 100 μ g per injection. Animals were kept alive for 12 hrs to 48 hrs post-injection to permit migration of the injected protein, and in no case were any tetanus symptoms detected. The mice were sacrificed by intracardiac perfusion with 4% paraformaldehyde in PBS while under deep anesthesia. Brains were harvested, rinsed in PBS and incubated in 15% sucrose overnight at 4 C, then

mounted in tissue-tek before sectioning, 15 μm thick slices using a cryostat.

EXAMPLE 5: **Histology, Immunohistology, and X-Gal staining.**

For *in toto* X-Gal staining of the dissected brain and tongue, mice (10 animals) were sacrificed and fixed as described above. The brain was further cut with a scalpel along a median plane and directly incubated for 12 hrs in X-Gal solution.

For immunohistology, sections were incubated in a 1:5000 dilution of anti-TTC antibody in 2% BSA/0.02% Triton X-100 in PBS overnight at 4 C after nonspecific antibody binding sites were blocked by a 1 hr incubation in the same buffer. Antibody detection was carried out using the Vectastain ABC-alkaline phosphatase kit with DAB color development. For X-Gal staining, sections were incubated in X-Gal solution and counterstained for 30 sec with hematoxylin 115 (v/v) in PBS. Histology on adjacent sections was done after X-Gal staining, using a 30 sec incubation in hematoxylin/thionin solution. All sections were mounted in moviol before eight microscopy analysis.

EXAMPLE 6A: **Internalization of the -gal-TTC fusion protein by neurons *in vitro*.**

Differentiation of 1009 cells with retinoic acid and cAMP *in vitro* yields neuronal and glial cells (18, 20). X-Gal staining or immunolabeling were performed after incubation with the -gal-TTC fusion protein or with either the -gal or TTC proteins alone. Only when the hybrid protein was incubated with differentiated

1009 cells was a strong X-Gal staining detected in cells having a neuronal phenotype. No signal was detected when -gal alone was incubated under the same conditions. A similar X-Gal staining pattern was obtained after pronase treatment of the cells to remove surface bound proteins, indicating that the hybrid protein had been internalized. The intracellular localization of the hybrid protein was further confirmed by electron microscopic analysis of X-Gal-stained cells. Furthermore, the enzymatic activity observed in axons seemed to be localized in vesicles associated with filaments, which is in agreement with previous work on TTC fragment or native tetanus toxin (14, 21, 22). Co-labeling with anti-TTC and anti-neurofilament antibodies revealed that -gal activity co-localized with TTC fragment in neuronal cells. No glial cells were labeled with either antibody.

EXAMPLE 6B: Internalization of the TTC- -gal fusion protein by neurons *in vitro*.

The method used for the internalization was identical to that described in Example 6 above. The results show efficiently internalization of the hybrid as in Example 6 above.

EXAMPLE 7: Retrograde transport of the hybrid protein *in vivo*.

To study the behavior of the -gal-TTC protein *in vivo*, the hybrid protein was tested in a well characterized neuronal network, the hypoglossal system. After intramuscular injection of -gal-TTC protein into the mouse tongue, the distribution of the hybrid

protein in the CNS was analyzed by X-Gal staining. Various dilutions of the protein were injected and sequential time points were analyzed to permit protein transport into hypoglossal motoneurons (XII), and its further transneuronal migration into connected second order neurons.

A well-defined profile of large, apparently retrogradely labeled neurons was clearly evident in the hypoglossal structure, analyzed *in toto* at 12 hrs post-injection. A strong labeling was also apparent in the hypoglossal nerve (XII_n) of the tongue of the injected mice. At the level of muscle fibers, button structures were observed that might reflect labeling of neuromuscular junctions where the hybrid protein was internalized into nerve axons. These data demonstrate that the -gal-TTC hybrid protein can migrate rapidly by retrograde axonal transport as far as motoneuron cell bodies, after prior uptake by nerve terminals in the tongue. This specific uptake and the intraaxonal transport are similar to the properties that have been described for the native toxin (6, 21, 23).

Transport of the hybrid protein was examined in greater detail by analyzing X-Gal-stained brain sections. Motoneurons of the hypoglossal nucleus became labeled rapidly, with 12 hrs being the earliest time point examined. Most of the label was confined to neuronal somata, the cell nuclei being unlabeled. The intensity of the labeling depends upon the concentration of the -gal-TTC protein injected: when 10 µg of protein was injected, only the hypoglossal somata were detected, whereas with 25 to 50 µg a fuzzy

network of dendrites was visualized; transsynaptic transfer was detected with 100 µg of hybrid protein. An identical distribution of label was observed then brain sections were immunostained with an anti-TTC antibody, demonstrating that -gal and TTC fragment co-localize within cells. Finally, injection of -gal alone did not result in labeling of the hypoglossal nuclei and therefore confirms that transport of the hybrid protein is TTC-dependent. Labeling with an anti-TTC antibody was less informative than detection of -gal activity; for instance, the nerve pathway to the brain could not be visualized by anti-TTC immunostaining. At 18 hrs post-injection, labeling was observed in the hypoglossal nuclei: all motoneuron cell bodies and the most proximal part of their dendrites were very densely stained. In contrast, no labeling was ever detected in glial cells adjoining XII motoneurons or their axons. Our results are in accordance with others who reported an identical pattern of immunolabeling after injection of the TTC fragment alone (9). Transneuronal transfer is detectable after 24 hrs. An additional 24 hrs and beyond did not yield a different staining.

EXAMPLE 8: Transneuronal transport of the hybrid protein.

Second order interneurons, as well as higher order neurons that synapse with the hypoglossal motoneurons, have been extensively analyzed using conventional markers, such as the wheat germ agglutinin-horseradish peroxidase complex (WGA-HRP) or neurotropic viruses such as alpha-herpes (24) and rhabdoviruses (25). An

exhaustive compilation of regions in the brain that synaptically connect to the hypoglossal nucleus has also been described recently (25). In this invention, the distribution of the -gal-TTC fusion depended on the initial concentration of protein injected into the muscle and the time allowed for transport after injection. Up to 24 hrs post-injection, labeling was restricted to the hypoglossal nuclei. After 24 hrs, the distribution of second order transneuronally labeled cells in various regions of the brain was consistent and reproducible. Even at longer time points (e.g. 48 hrs), labeling of the hypoglossal nucleus remained constant. At higher magnification, a discrete and localized staining of second-order neurons was observed, suggesting that the hybrid protein had been targeted to vesicles within cell somata, synapses and axons. A similar patchy distribution was previously described for tetanus toxin and TTC fragment alone (14, 21, 22).

Intense transneuronal labeling was detected in the lateral reticular formation (LRF), where medullary reticular neurons have been reported to form numerous projections onto the hypoglossal nucleus (26, 27). -gal activity was detected bilaterally in these sections. Label led LRF projections formed a continuous column along the rostrocaudal axis, beginning lateral to the hypoglossal nucleus, with a few neurons being preferentially stained in the medullary reticular dorsal (MdD) and the medullary reticular ventral (MdV) nuclei. This column extends rostrally through the medulla, with neurons more

intensely labeled in the parvicellular reticular nucleus (PCRt, caudal and rostral). After 48 hrs, cells in MdD and PCRt were more intensely stained. A second bilateral distribution of medullary neurons projecting to the hypoglossal nucleus was detected in the solitary nucleus (Sol) but the labeling was less intense than in the reticular formation, presumably because relatively few cells of the solitary nucleus project onto the hypoglossal nucleus (26). However, no labeling was found in the spinal trigeminal nucleus (Sp5), which has also been shown to project onto the hypoglossal nucleus (26). Transsynaptic transport of the -gal-TTC protein was also detected in the pontine reticular nucleus caudal (PnC), the locus coeruleus (LC), the medial vestibular nucleus (MVe) and in a few cells of the inferior vestibular nucleus (IV). These cell groups are known to project onto the hypoglossal nucleus (25), but their labeling was weak, probably because of the greater length of their axons. A few labeled cells were observed in the dorsal paragigantocellular nucleus (DPGi), the magnocellular nucleus caudal (RMc), and the caudal raphe nucleus (R); their connections to the hypoglossal nucleus have also been reported (25). Finally, labeled neurons were detected bilaterally in midbrain projections, such as those of the mesencephalic trigeminal nucleus (Me5), and a few neurons were stained in the mesencephalic central gray region (CG). These latter nuclei have been typed as putative third order cell groups related to the hypoglossal nucleus (25).

Neurons in the motor trigeminal nucleus (Mo5) and the accessory trigeminal tract (Acs5) were also labeled, along with a population of neurons in the facial nucleus (N7). However, interpretation of this labeling is more ambiguous, since it is known that motoneurons in these nuclei also innervate other parts of the muscular tissue, and diffusion of the hybrid protein might have occurred at the point of injection. Conversely, these nuclei may have also projected to the tongue musculature via nerve XII, since neurons in N7 have been reported to receive direct hypoglossal nerve input (28). This latter explanation is consistent with the fact that labeling in these nuclei was detected only after 24 hrs; however, this point was not further investigated.

Altogether, the data summarized in Table 1 clearly establish transneuronal transport of the β -gal-TTC fusion protein from the hypoglossal neurons into several connected regions of the brainstem.

Table 1. Transneuronal transport of the lacZ-TTC fusion from the XII nerve: labeling of different cell types in the central nervous system.

Cell groups	12-18 hrs	24-48 hrs
First order neurons		
First category:		
XII, hypoglossal motoneurons	++	+++
Second category:		
N7, facial nu	-	++
Mo5, motor trigeminal nu	-	++
Acs5, accessory trigeminal nu	-	+
Second order cell groups		
MdD, medullary reticular nu, dorsal	-	++
MdV, medullary reticular nu, ventral	-	+/-
PCRt, parvicellular reticular nu, caudal	-	++
PCRt, parvicellular reticular nu, rostral	-	++
Sol, solitary tract nu	-	+
DPGi, dorsal paragigantocellular nu	-	+/-
PnC, pontine reticular nu, caudal	-	+
RMc, magnocellular reticular nu	-	+/-
R, caudal raphe nu	-	+/-
MVe, medial vestibular nu	-	+
IV, inferior vestibular nu	-	+/-
LC, locus coeruleus	-	+
Me5, mesencephalic trigeminal nu (*)	-	+
CG, mesenphalic central gray (*)	-	+/-

(*) Represents second order cell groups that also contain putative third order neurons (see text). -, no labeling; + to +++, increased density of label; +/- weak labeling. 16 animals were analysed for the 12-18 hrs p.i. data; 6 animals were analysed for the 24-48 hrs p.i. data.

REFERENCES

The following publications, which have been cited herein, are relied upon and incorporated by reference in their entireties herein.

1. Eisel, U., Jarausch, W., Goretzki, K., Henschen, A., Engels, J., Weller, U., Hudel, M., Habermann, E. & Niemann, H. (1986) *EMBO J.* 5, 2495-2502.
2. Fairweather, N. F. & Lyness, V. A. (1986) *Nucleic Acids Res.* 14, 7809-7812.
3. Montecucco, O. & Schiavo, G. (1995) *Quart. Rev. Biophys.* 28, 423-472.
4. Schwab, M. E. & Thoenen, H. (1976) *Brain Res.* 105, 213-227.
5. Schwab, M. E. & Thoenen, H. (1977) *Brain Res.* 122, 459-474.
6. Price, D. L., Griffin, J. W. & Peck, K. (1977) *Brain Res.* 121, 379-384.
7. Bizzini, B., Stoeckel, K. & Schwab, M. (1977) *J. Neurochem.* 28, 529-542.
8. Evinger, O. & Erichsen, J. T. (1986) *Brain Res.* 380, 383-388.

9. Fishman, P. S. & Carrigan, D. R. (1987) *Brain Res.* 406, 275-279.
10. Manning, K. A., Erichsen, J. T. & Evinger, O. (1990) *Neurosci.* 34, 251-263.
11. Halpern, J. L., Habig, W. H., Neale, E. A. & Stibitz, S. (1990) *Infection and Immunity* 58, 1004-1009.
12. Bizzini, B., Grob, P., Glicksman, M. A. & Akert, K. (1980) *Brain Res.* 193, 221-227.
13. Dobrenis, K., Joseph, A. & Rattazzi, M. G. (1992) *Proc. Natl. Acad. Sci. USA* 89, 2297-2301.
14. Fishman, P. S. & Savitt, J. M. (1989) *Exp. Neurol.* 106, 197-203.
15. Beaude, P., Delacour, A., Bizzini, B., Domuado, D. & Remy, M. H. (1990) *Biochem.* 271, 87-91.
16. Francis, J.W., Hosler, B. H., Brown, R. H., Jr. & Fishman, P. S. (1995) *J. Biol. Chem.* 270, 15434-15442.
17. Fellous, M., Gunther, E., Kemler, R., Weils, J., Berger, R., Guenet, J. L., Jakob, H. & Jacob, F. (1978) *J. Exp. Med.* 148, 58-70.
18. Jakob, H. & Nicolas, J. F. (1987) *Methods Enzymol.* 151, 66-84.

19. Whitehouse, R. L. S., Benichou, J. O. & Ryter, A. (1977) *Biol. Cell.* 30, 155-158.
20. Wojcik, B. E., Nothias, F., Lazar, M., Jouin, H., Nicolas, J. F. & Peschanski, M. (1993) *Proc. Natl. Acad. Sci. USA* 90, 1305-1309.
21. Price, D. L., Griffin, J., Young, A., Peck, K. & Stocks, A. (1975) *Science* 188, 945-947.
22. Matteoli, M., Verderio, C., Rossetto, O., Iezzi, N., Ooco, S., Schiavo, G. & Montecucco, G. (1996) *Proc. Natl. Acad. Sci. USA* 93, 13310-13315.
23. Stockel, K., Schwab, M. & Thoenen, H. (1975) *Brain Res.* 99, 1-16.
24. Ugolini, G. (1995a) in *Viral Vectors: Gene Therapy and Neuroscience Applications*, eds. Loewy, A. D. & Kaplitt M. G. (New York: Academic Press), pp. 293-317.
25. Ugolini, G. (1995b) *The Journal of Comparative Neurology* 356, 457-480.
26. Borke, R. C., Nau, M. E. & R.L Ringler, J. (1983) *Brain Research* 269, 47-55.

27. Horst, G. T. T., Copray, J. C. V. M., liem, R. S. B. & Willigen, J. D. V. (1991) *Neuroscience* 40, 735-758.
28. O'Reilly, P. M. R. & Fitzgerald, M. J. T. (1990) *J. Anat.* 172, 227-243.
29. Chalfie, M.. Tu, Y., Euskirchen, G., Ward, W. W. & Prasher, D. C. (1994) *Science* 263, 802-805.
30. Miesenböck, G. & Rothman, J. E. (1997) *Proc. Natl. Acad. Sci. USA* 94, 3402-3407.
31. Le Mouellic, H., Lallemand, Y. & Brûlet, P. (1990) *Proc. Natl. Acad. Sci. USA* 87, 4712-4716.
32. Le Mouellic, H., Lallemand, Y. & Brûlet, P. (1992) *Cell* 69, 251-264.
33. Mombaerts, P., Wang, F., Dulac, C.. Chao, S. K., Nemes, A., Mendelsohn, M., Edmondson, J. & Axel, R. (1996) *Cell* 87, 675-686.
34. Mountford, P. S. & Smith, A. G. (1995) *Trends Genet.* 11, 179-184.
35. Rosen, D. R. & al (1993) *Nature* 362, 59-62.
36. Lefebvre, S., Büglen, L., Reboullet, S.. Clermont, O., Bürlet, P., Viollet, L, Benichou, B., Cruaud, O., Millasseau, P., Zeviani, M.,

Paslier, D.L., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A. & Melki, J. (1995) *Cell* 80, 155-165.

37. Roy, N. & al (1995) *Cell* 80, 167-178.

38. Wolfe, J. H., Deshmane, S. L. & Fraser, N. W. (1992) *Nature genetics* 1, 379- 384.

39. Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., McDonald, M. P., Crawley, J. N., Sandhoff, K., Suzuki, K. & Proia, R. L. (1995) *Nature Genetics* 11, 170-176.

40. Duarte, R. G. (1995) *Neurologia* 1, 56-61.

41. Ghadge, G. D., Roos, R. P., Kang, U. J., Wollmann, R., Fishman, P. S., Kalynych, A. M., Barr, E. & Leiden, J. M. (1995) *Gene Therapy* 2, 132-137.

What is claimed is:

1. A method for *in vivo* delivery of a desired composition into human or animal central nervous system (CNS) or spinal cord, wherein the method comprises administering to the human or animal a composition comprising a non-toxic, proteolytic fragment of tetanus toxin (TT) in association with at least a molecule having a biological function and said composition is capable of *in vivo* retrograde axonal transport and transsynaptic transport into the CNS or the spinal cord of the human or animal and of being delivered at different areas of the CNS or the spinal cord.
2. The method according to claim 1, wherein the composition is administered into a muscle.
3. The method according to claim 2, wherein the composition is administered into a muscle in the vicinity of a neuromuscular junction.
4. The method according to claim 2, wherein the muscle is selected in relation with the desired area of the CNS or spinal cord.
5. The method according to claim 1, wherein the composition is administered into neuronal cells.
6. The method according to claim 1, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues in association with at least a molecule having a biological function selected from the group consisting of a protein for compensation or modulation of functions under the control of the CNS or the spinal cord or modulation of functions in the CNS or the

spinal cord or a protein to be delivered by gene therapy expression system to the CNS or the spinal cord.

7. The method according to claim 1, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxin (TT) comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues and a fraction of a fragment A devoid of its toxic activity corresponding to the proteolytic domain having a zinc-binding motif located in the central part of the chain between amino acids 225 and 245 in association with at least a molecule having a biological function selected from the group consisting of protein for the compensation or the modulation of functions under the control of the CNS or the spinal cord or protein to be delivered by gene therapy expression system to the CNS or the spinal cord.

8. The method according to claim 6 or claim 7, wherein the molecule is selected from the group consisting of protein SM, BDNF (Brain-derived neurotrophic factor), NT-3 (Neurotrophin-3), NT-4/5, GDNF (Glial cell-line-derived neurotrophic factor), IGF (Insulin-like growth factor), PNI (protease nexin I), SPI3 (Serine Protease Inhibitor protein), ICE (Interleukin-1 converting enzyme), Bcl-2, GFP (green fluorescent protein), endonucleases like I-SceI or CRE, antibodies, or drugs specifically directed against neurodegenerative diseases such as latero spinal amyotrophy (LSA).

9. The method according to claim 8, wherein the composition comprises a combination of at least two of said molecules.

10. The method according to claim 8, wherein the molecule is located upstream from the fragment of tetanus toxin.

11. The method according to claim 8, wherein the molecule is located downstream from the fragment of tetanus toxin.

12. The method according to claim 1, which comprises administering to the human or animal a vector containing nucleotides encoding the composition, wherein the vector is capable of *in vivo* expression in a muscle and this product is capable of migrating to the CNS or spinal cord.

13. The method according to claim 12, wherein said vector comprises a promoter and an enhancer capable of expressing the nucleotides contained in said vector in the muscle.

14. The method according to claim 13, wherein said vector is the plasmid pCMV-LacZ-TTC which has been deposited at the C.N.C.M. on August 12, 1997, under the registration number I-1912.

15. The method according to claim 12 or 13, wherein said vector is administered into the muscle.

16. The method according to claim 12 or 13, wherein the molecule is a nucleotide encoding for a protein or a polypeptide linked chemically to the fragment of tetanus toxin and being transported and expressed directly in neurons.

17. A hybrid fragment of tetanus toxin comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues capable of transferring *in vivo* a protein, a peptide, or a polynucleotide through a neuromuscular junction and at least one synapse.

18. A hybrid fragment of tetanus toxin comprising a fragment C and a fragment B or a fraction thereof of at least 11 amino acid residues and a fraction of a fragment A devoid of its toxic activity corresponding to the proteolytic domain having a zinc-binding motif located in the central part of the chain between amino acids 225 and 245 capable of transferring *in vivo* a protein, a peptide or a polynucleotide through a neuromuscular junction and at least one synapse.

19. An amino acid variant fragment having the same properties as the hybrid fragment of tetanus toxin according to claims 17 or 18.

20. A polynucleotide variant fragment encoding an amino acid variant fragment according to claim 19, which is capable of hybridization under stringent conditions with the natural tetanus toxin sequence.

21. A composition containing an active molecule in association with a hybrid fragment of tetanus toxin according to claims 17 or 18 or with an amino acid variant fragment according to claim 16.

22. The composition according to claim 21, wherein the active molecule is selected from the group consisting of protein SMN, BDNF (Brain-derived neurotrophic factor), NT-3, NT-4/5, GDNF (Glial cell-line derived neurotrophic factor), IGF (Insulin-like

growth factor), PNI (protease nexin I), SP13 (Serine Protease Inhibitor protein), ICE, Bcl-2, GFP (green fluorescent protein), endonucleases like I-SceI or CRE, antibodies or drugs specifically directed against neurodegenerative diseases such as latero spinal amyotrophy (LSA).

23. The composition according to claim 21, wherein the active molecule is a polynucleotide encoding a protein or a polypeptide with a promoter capable of expression in neurons, and optionally an enhancer.

24. A vector comprising a promoter capable of expression in muscle cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin according to claims 17 or 18 or with an amino acid variant fragment according to claim 19 associated with a polynucleotide coding for a protein or a polypeptide.

25. A cell or vector comprising a promoter capable of expression in neuronal cells or precursors of neuronal cells and optionally an enhancer, a nucleic acid sequence coding for the fragment of tetanus toxin according to claims 17 or 18 or for an amino acid variant fragment according to claim 19, associated with a polynucleotide coding for a protein or a polypeptide.

26. A composition for the treatment of a patient or an animal affected with CNS or spinal cord disease, which comprises delivering a composition according to claims 21, 22, or 23 to the patient or animal in an amount effective for treatment of the CNS or spinal cord disease.

27. A composition for the treatment of a patient or an animal affected with CNS or spinal cord disease, which comprises delivering a vector according to claim 24 or a cell according to claim 25 to the patient or animal in an amount effective for treatment of the CNS or spinal cord disease.

28. The method according to claim 1, which comprises administering to the human or animal a cell or a vector containing nucleotides encoding the composition, wherein the cell or vector is capable of *in vivo* expression in neuronal cells or precursor of neuronal cells and wherein said cell is reimplanted into the CNS or spinal cord.

29. The method according to claim 28 wherein said cell or vector comprises a promoter and an enhancer capable of expressing the nucleotides contained in said cell in neuronal cells or precursors of neuronal cells.

30. The method according to claim 28 or 29 wherein the molecule is a polynucleotide encoding for a protein or a polypeptide linked chemically to the fragment of tetanus toxin and being expressed directly in neurons.

31. Use of a hybrid fragment of tetanus toxin according to claim 18 or 19 or of a polynucleotide fragment according to claim 20, or a composition according to anyone of claims 21 to 23, or a vector according to claim 24, for the preparation of a composition for the treatment of the CNS or spinal cord disease.

SK-TTC. -> Genes

FIGURE 1A

DNA sequence	1600 b.p.	ggaaacacgtat ... gtcgttttacaa	linear
--------------	-----------	-------------------------------	--------

1 ggaaacacgtatgaccatgattacgccaaggctcgaaatataaccctcaactaaaggaaacaaaggctggagctcggtacccg 80
 81 ggccacc ATG GTT TTT TCA ACA CCA ATT CCA TTT TCT TAT TCT AAA ATT CTG GAT TGT TGG 141
 1 M V F S T P I P F S Y S K N L D C W 18
 142 GTT GAT AAT GAA GAT ATA GAT GTT ATA TTA AAA AAG AGT ACA ATT TTA AAT TTA GAT 201
 19 V D N E E D I D V I L K S T I L N D 38
 202 ATT AAT AAT GAT ATT ATA TCA GAT ATA TCT CGG TTT AAT TCA TCT GTA ATA ACA TAT CCA 261
 39 I N N D I S D I S G F N S S V I T Y P 58
 262 GAT GCT CAA TTG GTG CCC CGA ATA ATT GCC AAA GCA ATA CAT TTA GTA AAC ATT GAA TCT 321
 59 D A Q L V P G I N G K A I H L V N N E S 78
 322 TCT GAA GTT ATA GTG CAT AAA GCT ATT GAA TAT GAT ATT GAT ATG ATT AAT ATT TTT 381
 79 S E V I V H K A M D I E Y N D M F N N F 98
 382 ACC GTT AGC TTT TGG TTG AGG GTT CCT AAA GTA TCT GCT AGT CAT ATT GAA CAA TAT GGC 441
 99 T V S F W L R V P K V S A S H L E Q Y G 118
 442 ACA AAT GAG TAT TCA ATA ATT AGC TCT ATT AAA AAA CAT AGT CTA TCA ATA CGA TCT GCT 501
 119 T N E Y S I I S M K K H S L S I G S G 138
 502 TGG AGT GTA TCA CCT AAA GGT ATT AAC TTA ATA TGG ACT TTA AAA GAT TCC GCG GGA GAA 561
 139 W S V S L K G N N L I W T L K D S A G E 158
 562 GTT AGA CAA ATA ACT TTT AGG GAT TTA CCT GAT AAA ATT ATT GCT ATT TTA GCA ATT AAA 621
 159 V R Q I T F R D L P D K F N A Y L A N K 178
 622 TGG GTT ATA ACT ATT ACT ATT GAT AGA TTA TCT GCT ATT TTG ATT ATA ATT GGA 681
 179 W V F I T I T N D R L S S A N L Y I N G 198
 682 GTA CTT ATG GGA AGT GCA GAA ATT ACT GGT TTA GCA GCT ATT AGA GAG GAT ATT ATT ATA 741
 199 V L M G S A E I T G L G A I R E D N N I 218
 742 ACA TTA AAA CTA GAT AGA TGT ATT ATT ATT CAA TAC GTT TCT ATT GAT AAA TTT AGG 801
 219 T L K R C N N Q Y V S I D K F R 238

2 / 8

FIGURE 1B

FIGURE 2




FIGURE 3A




FIGURE 3B




FIGURE 4A





FIGURE 4B



pCMV.LACZ.TTC -> Graphic Map

DNA sequence 8519 b.p. tagtttattata ... acggccatgcat circular




FIGURE 5